The evolving first-line treatment of advanced non-small cell lung cancer harbouring epidermal growth factor receptor mutations

Παρόμοια τεκμήρια

• Is there a third line option after chemotherapy and TKI failure in advanced non-small cell lung cancer?
  ανά: De Grève, Jacques, κ.ά.
  Έκδοση: (2012)
• Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib
  ανά: Noeparast, Amir, κ.ά.
  Έκδοση: (2016)
• First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell lung cancer
  ανά: Greenhalgh, Janette, κ.ά.
  Έκδοση: (2021)
• Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations
  ανά: Holleman, Marscha S., κ.ά.
  Έκδοση: (2019)
• The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer
  ανά: Low, Jia Li, κ.ά.
  Έκδοση: (2019)